Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research talks about the antibody drug conjugate against BCMA – 60% response rate in refractory myeloma at MOASCs Spotlight On® Hematology in Huntington Beach.
Antibody Drug Conjugate Against BCMA – 60% Response Rate in Refractory Myeloma
